Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis ; day:8 ; month:12 ; year:2021 ; pages:1-19
Rheumatology and therapy ; (8.12.2021), 1-19
- Urheber
-
Jabado, Omar
Maldonado, Michael A.
Schiff, Michael
Weinblatt, Michael E.
Fleischmann, Roy
Robinson, William H.
He, Aiqing
Patel, Vishal
Greenfield, Alex
Saini, Jasmine
Galbraith, David
Connolly, Sean E.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-021-00404-x
- URN
-
urn:nbn:de:101:1-2022021019583872406199
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jabado, Omar
- Maldonado, Michael A.
- Schiff, Michael
- Weinblatt, Michael E.
- Fleischmann, Roy
- Robinson, William H.
- He, Aiqing
- Patel, Vishal
- Greenfield, Alex
- Saini, Jasmine
- Galbraith, David
- Connolly, Sean E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry